Artiva Biotherapeutics, Inc. (ARTV) stock
ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.78−0.05 (-1.31%)
Close on Nov 20, 2026Market cap $184.81MP/E –Yield –
Artiva Biotherapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Artiva Biotherapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$76.91M. For fiscal 2025 it was -$79.34M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$79.34M | – |
| FY2024 | Dec 31, 2024 | -$55.67M | – |
| FY2023 | Dec 31, 2023 | -$50.69M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$20.77M | – |
| Q1 FY2026 | Mar 31, 2026 | -$21.19M | – |
| Q4 FY2025 | Dec 31, 2025 | -$15.15M | – |
| Q3 FY2025 | Sep 30, 2025 | -$19.80M | – |
| Q2 FY2025 | Jun 30, 2025 | -$24.04M | – |
| Q1 FY2025 | Mar 31, 2025 | -$20.35M | – |
| Q4 FY2024 | Dec 31, 2024 | -$14.71M | – |
| Q3 FY2024 | Sep 30, 2024 | -$11.71M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.15M | – |
| Q1 FY2024 | Mar 31, 2024 | -$15.10M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.31M | – |
| Q3 FY2023 | Sep 30, 2023 | -$10.93M | – |
See a number that looks wrong?